Application for production of recombinant human thymosin α 1, the first gene new drug in China, accepted

According to the public data, thymic hormone immunomodulators can regulate the development, differentiation and maturation of T-lymphocytes They are mainly used in the treatment of viral infectious diseases, including hepatitis B, hepatitis C, lung cancer, melanoma and other malignant tumors, and enhance the immune function of the body Thymosin products include thymosin, thymopentin and thymosin α 1 Among them, thymosin α 1 is a high-end product of thymosin, which has high immune enhancement activity It is worth mentioning that, compared with the chemical synthesis of thymosin α 1 on the market, the products of kinsai pharmaceutical industry adopt the gene synthesis process, which have basically the same structure and lower cost of raw materials, and have the price advantage CFDA website information shows that at present, there is no domestic enterprise to obtain the production approval document of recombinant human thymosin α 1, and only one Jinsai pharmaceutical company has applied for production At the same time, thymosin α 1 (thymus method) has been produced by Shuangcheng pharmaceutical, Hainan Zhonghe pharmaceutical, Chengdu Di'ao Jiuhong pharmaceutical factory, Chengdu shengnuo biopharmaceutical, etc Thymosin is the best-selling and fastest-growing chemical synthetic polypeptide in the Chinese market in recent years, according to a securities trader After the listing of recombinant human thymosin α 1 in Jinsai pharmaceutical, it is expected to seize market share quickly by virtue of its price advantage.